Shire Receives Breakthrough Therapy Designation for Rare Diseases Drugs

by Reshma Anand on  June 16, 2016 at 4:13 PM Corporate News
RSS Email Print This Page Comment
US Food and Drug Administration has granted breakthrough therapy designation for two experimental drugs for rare diseases conducted by the biotechnology company Shire.
Shire Receives Breakthrough Therapy Designation for Rare Diseases Drugs
Shire Receives Breakthrough Therapy Designation for Rare Diseases Drugs
Advertisement

Shire has produced positive results for the two drugs in its Phase-II trials. One of the drug is budesonide for eosinophilic esophagitis (EoE) and another is maralixibat for progressive familial intrahepatic cholestasis type 2 (PFIC2).

Advertisement
Eosinophilic Esophagitis is a rare immune system disease occurring due to the accumulation of eosinophils, a type of white blood cells, in the lining of the esophagus, resulting in inflammation.

Budesonide has shown positive results against the disease in the phase -II trial. Now, the company is testing the drug in adolescents and adults ages 11-55 years with EoE in the phase-III trial.  

Progressive familial intrahepatic cholestasis type 2 is a group of autosomal-recessive liver disorders developing during infancy. It usually progresses into cirrhosis  The experimental drug maralixibat has reduced serum bile acids, skin itching, leading to normalization of liver in some patients tested in the phase-II trial. 

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Drug Toxicity Reiki and Pranic Healing Drugs Banned in India Basics of Rare Diseases Incurable Diseases 
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive